Drug Profile
Cetuximab biosimilar - R-Pharm
Alternative Names: Erbitux biosimilar - R-Pharm; RPH-002Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator R-Pharm
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Colorectal cancer; Head and neck cancer
Most Recent Events
- 08 Oct 2021 Phase III trial is still ongoing for Head and neck cancer and Colorectal cancer in Russia (R-Pharm pipeline, October 2021)
- 04 Sep 2017 Cetuximab biosimilar is still in clinical trials for Head and neck cancer (R-Pharm pipeline, August 2017)
- 15 May 2015 R-Pharm announces intention to submit MAA in Russia and Turkey in 2015